UBS analyst Ashwani Verma raised the firm’s price target on Immunovant (IMVT) to $18 from $17 and keeps a Neutral rating on the shares. UBS remains cautious on the Immunovant story due to limited/no catalyst until 2027, as well as a financing overhang, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant 3M share Block Trade priced at $17.85
- Immunovant 3M share Block Trade; price range $17.85-$18.00
- Immunovant resumed with a Neutral at Goldman Sachs
- Immunovant’s IMVT-1402: A Promising Solution for Unmet Needs in Graves’ Disease
- 3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts